Governance and Society Leadership

Board of Directors

2020 - 2021

President, Yvonne Perrie, Ph.D.


Yvonne Perrie is Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland. She gained her PhD from the University of London (1998) investigating the role of liposomes for drug delivery. She then worked developing liposome drug delivery platform technology. Yvonne joined Aston University in 2000 and was appointed Professor in Drug Delivery in 2007. In 2016, Yvonne moved to the University of Strathclyde as part of the Global Talent Appointment Programme. Yvonne’s research is multi-disciplinary and is focused on the development of drug delivery systems to facilitate the delivery of drugs and vaccines.

President-Elect, Ben Boyd, Ph.D.

 


Prof Ben Boyd is a colloid and physical chemist with a Ph.D. from the University of Melbourne (1999). After industry experience in the explosives and pharmaceutical industries, he commenced an academic position at Monash Institute of Pharmaceutical Sciences (MIPS) in 2004. His research group focuses on colloidal and structural aspects of lipids, lipid self-assembly and pharmaceutical systems, focused on controlling materials at the colloidal scale for delivery in pharma and other fields. His group is also active in developing new synchrotron X-ray-based characterization approaches for lipid and solid-state systems and they have published over 250 papers and received over 10000 citations. He is an elected Fellow and past Secretary of the Controlled Release Society (CRS), Past President of the Australian Chapter of CRS and is currently President of the Australian Colloid and Interface Society. He serves on the editorial boards of several journals including Co-editor of the Journal of Colloid and Interface Science and Editor for Asia for Drug Delivery and Translational Research.

Immediate Past-President, Justin Hanes, Ph.D.

 


Dr. Hanes is the Lewis J. Ort Professor of Ophthalmology with joint appointments in Biomedical Engineering, Chemical & Biomolecular Engineering, Neurosurgery, Oncology, and Pharmacology & Molecular Sciences at the Johns Hopkins University. His degrees are in Chemical Engineering from UCLA (B.S.) and MIT (Ph.D.), and he has completed a postdoctoral fellowship in Oncology and Neurosurgery at Johns Hopkins prior to beginning his faculty position in 1998. Professor Hanes is the Director of the Center for Nanomedicine at the Johns Hopkins University School of Medicine.

Secretary, Ilva Rupenthal, Ph.D.


Dr. Rupenthal is an Associate Professor in the Department of Ophthalmology and the Director of the Buchanan Ocular Therapeutics Unit at the University of Auckland, New Zealand, which aims to translate ocular therapeutic related scientific research into the clinical setting, whether pharmaceutical, cell or technology-based. Her team is researching various drugs and drug delivery systems for the management of inflammatory and degenerative eye conditions, with some of the patented technologies licensed to biotechnology companies. She is a Special Issue Editor for Drug Delivery and Translational Research and as current Director-at-Large acts as the Local Chapter Board Liaison.

 

Treasurer, Cornell Stamoran, Ph.D.


Cornell Stamoran has thirty years’ experience across a broad range of disciplines, including accounting and finance, strategy, M&A, innovation, IT, advocacy (IR, PR, Gov’t), and sales and marketing. Cornell began his career with five years in Arthur Andersen & Co.’s accounting and audit practice. Cornell then joined drug delivery provider R.P. Scherer Corporation, first focusing on finance and IT, then migrating to strategy and innovation. Following Cardinal Health’s acquisition of Scherer, Cornell continued his migration to growth-related functions, including building global business development and sales operations teams, establishing a strategic marketing function, and supporting M&A. Following Catalent’s spin-out in 2007, Cornell has been accountable for branding and marketing; public, investor, and government relations; market intelligence and strategy; and innovation and regulatory policy, including as a member of the industry negotiating team for GDUFA reauthorization. Cornell holds a B.S.A. with honors from the University of Michigan (accounting and finance), and a Ph.D. in history. He holds/has held a variety of professional certifications including Certified Public Accountant, Certified Management Accountant, Certified Information Systems Auditor, Certified Licensing Professional, Certified Systems Engineer, Lean-Six Sigma Green Belt, and is completing a RAPS regulatory affairs certificate. Cornell currently serves as Co-Chair of the Catalent Applied.

Treasurer-Elect, Maria-Teresa Peracchia, Ph.D.


Maria Teresa Peracchia, Ph.D., is the Global Head, Drug Delivery and Product Integration within Biologics Drug Product Development (BioDPD) since March 2019. In her role, Maria Teresa is in charge of the drug delivery strategy of Biologics at Sanofi and coordinates internal activities and external collaborations.

Maria Teresa joined Sanofi in 1999. She has been instrumental in achieving the successful approval and launch of Dupilumab (Dupixent®) developed in collaboration with Regeneron, where she led the CMC team for Atopic Dermatitis and Asthma indications.  Through her leadership, Maria-Teresa gained broad exposure to development strategies and issues encountered during the development of biologics.

Prior to this, Maria-Teresa held several positions of increasing responsibility in the formulation and drug delivery groups within Sanofi. She has authored/ co-authored over 20 publications in the field of drug delivery and filed 8 patents.

Maria-Teresa holds a Ph.D. in Pharmacy from the University of Parma. She was a Visiting Scientist (1992-1994) in Prof. Robert Langer’s lab at MIT, developing PEGylated polymeric nanoparticles (Science, 1994) and a post-doctoral fellow (1995-1998) with Prof. Patrick Couvreur at the University Paris-XI.

Director-At-Large, Steve Little, Ph.D. (3-year term through 2021)

Little
Dr. Little currently holds the title of the William Kepler Whiteford Endowed Professor and Chair of Chemical Engineering at the University of Pittsburgh with appointments in Bioengineering, Pharmaceutical Sciences, Immunology, Ophthalmology and The McGowan Institute for Regenerative Medicine. He currently serves as Member-at-Large on the Board of Directors of the CRS, and also serves as the Program Chair for the 2020 Annual Meeting of the Society.  His prior contributions to the CRS include leading the establishment of the Focus Groups in the Society as well as the establishment of the Stars Collide Events at CRS Annual Meetings.  Dr. Little’s research focuses on controlled release systems that mimic biological function (biomimetic drug delivery).  He is also a Co-Founder of Qrono Inc. (a biomedical startup focused on controlled release-based cancer treatments) and OTERO Inc. (a biomedical startup focused on ocular drug delivery) and serves on the editorial boards of several journals in the field of controlled release and drug delivery.    

Director-At-Large, Twan Lammers, DSc, Ph.D. (3-year term through 2021)


Dr. Lammers obtained a D.Sc. degree in Radiation Oncology from Heidelberg University in 2008 and a Ph.D. degree in Pharmaceutics from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at the Institute for Experimental Molecular Imaging at RWTH Aachen University Clinic. In 2014, he was promoted to full professor of medicine at RWTH Aachen. Dr. Lammers has published over 200 research articles and reviews and has received several scholarships and awards, including a Starting, Consolidator and two Proof-of-Concept Grants from the European Research Council, and the Young Investigator Award of the Controlled Release Society. His primary research interests include drug targeting to tumors and to the brain and image-guided drug delivery. Within CRS, he has served as a Director-at-Large, as the Board Liaison for the Young Scientist Committee, as a member of the Programme Committee and as a member of the Young Investigator Award Committee. He was also one of the initiators in setting up recently founded the BeNeLux and France local chapter. He is an associate editor for Europe for the Journal of Controlled Release and serves on the editorial board of several additional journals, including Drug Delivery and Translational Research.

Director-at-Large, Alexander Kabanov, Ph.D. (3-year term through 2022)


Alexander Kabanov is a Mescal S. Ferguson Distinguished Professor at the Eshelman School of Pharmacy, the University of North Carolina at Chapel Hill, where he heads the Center for Nanotechnology in Drug Delivery and the Carolina Institute for Nanomedicine. He graduated from the Moscow State University in 1984, where he also received Ph.D. in 1987 and D.Sc. in 1990. Since 1994 he has worked in the United States. He introduced new concepts in nanomedicine including polymeric micelles, DNA/polycation complexes, block ionomer complexes, nanogels, nanoparticle-macrophage carriers and exosomes for delivery of small drugs, nucleic acids and polypeptides to treat cancers and diseases of the central nervous system. He invented the first polymeric micelle technology for cancer drug delivery to enter the clinical trials and co-founded pharmaceutical companies to develop products based on polymeric micelles. He published over 300 scientific papers, holds 35 US patents and was named the Highly Cited Researcher in Pharmacology and Toxicology. He has founded the Nanomedicine and Drug Delivery symposium series (www.nanodds.org), Carolina Nanoformulation Workshop, chaired Gordon Research Conferences, served on the CRS Board of Scientific Advisors, CRS Bioactive Materials Track Program Chair, and NIH study section chair. He received numerous awards and was elected to Academia Europaea, fellow of the CRS, NAI and AIMBE.

Director-at-Large, Katie Whitehead, Ph.D. (3-year term through 2022)


Kathryn A. Whitehead is an Associate Professor and Dean’s Career Fellow in the Departments of Chemical Engineering and Biomedical Engineering (courtesy) at Carnegie Mellon University. Her lab develops RNA and protein drug delivery systems and has a long-term goal of predicting the behavior of delivery materials in humans. She received an H.B.Ch.E Degree with Distinction from the University of Delaware (2002) and a Ph.D. in chemical engineering from the University of California, Santa Barbara (2007) before serving as an NIH Ruth L. Kirschstein Postdoctoral Fellow at the Massachusetts Institute of Technology (2008 – 2012). Prof. Whitehead is the recipient of numerous awards, including the NIH Director’s New Innovator Award, the DARPA Young Faculty Award, the DARPA Director’s Fellowship, the George Tallman Ladd Research Award, the CMBE Young Innovator Award, and the Kun Li Award for Excellence in Education. Prof. Whitehead was named as a Pioneer on the MIT Technology Review’s Innovators Under 35 list in 2014 as well as one of the Brilliant Ten by Popular Science in 2015. Her publications have been cited over 5,000 times, and several of her patents have been licensed and sublicensed for reagent and therapeutic use.

Director-At-Large, Yu-Kyoung Oh, Ph.D. (3-year term through 2023)


Yu-Kyoung Oh is a professor of the College of Pharmacy at Seoul National University, Republic of Korea. She is a fellow of the Korean Academy Science and Technology. She received bachelor's and master's degrees from Seoul National University, and a Ph.D. degree from State Univ. of New York at Buffalo in 1994. She obtained postdoctoral training at Harvard Medical School (1994-1996). Her research interests focus on the delivery of chemical drugs and nucleic acid-based drugs using versatile nanobiomaterials. She has published more than 190 SCI papers and received 26 patents. She received an excellent research award from Seoul National University (2015). She is active in working with various committees of Korean government and received awards from National Prime Minister of Korea (2013), the minister of Ministry of Science and ICT in Korea (2017), superb research award from the Pharmaceutical Society of Korea (2018), Hwandang award from the Korean National Academy of Science and Technology (2018), and Seoul culture award (2019) from the mayor of Seoul. She has experience in leadership in her department and academic societies. She had served as a vice dean at the College of Pharmacy at Seoul National University (2013-2017) and currently serves as a vice president for the Korean Society of Pharmaceutical Sciences and Technologies, the major society for drug delivery scientists in Korea. She had served as an associate editor for the Journal of Controlled Release (2015-2019). She is an associate editor for the Asian Journal of Pharmaceutical Sciences and an editorial board member for Advanced Drug Delivery Review. For the Controlled Release Society, she had participated as a member of the Annual Meeting Program Committee for the 2018 CRS meeting. From 2020, she serves as a Deputy Editor-in-Chief for the Journal of Controlled Release.